Drug Profile
IMM 101
Alternative Names: Heat-killed whole cell Mycobacterium obuense; IMM-101; NCTC 13365Latest Information Update: 13 Dec 2023
Price :
$50
*
At a glance
- Originator Immodulon Therapeutics
- Developer Canadian Cancer Trials Group; Erasmus MC; Immodulon Therapeutics; Ontario Institute for Cancer Research; Roche
- Class Antineoplastics; Antivirals; Bacteria; Immunotherapies
- Mechanism of Action Dendritic cell stimulants; Toll like receptor 2 agonists; Toll-like receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II Colorectal cancer; Malignant melanoma; Pancreatic cancer
- Phase I/II Cancer
Most Recent Events
- 11 Dec 2023 Immodulon plans a late-stage pivotal clinical trial for Pancreatic cancer (Intradermal)
- 10 May 2023 Immodulon plans a phase III trial for Pancreatic cancer (Intradermal) in combination with gemcitabine and paclitaxel
- 29 Mar 2023 Immodulon Therapeutics and Merck initiate a phase II PRIMUS-006 trial in Pancreatic cancer (Metastatic disease, First line therapy, Combination therapy) in United Kingdom (Intradermal) in March 2023 (ISRCTN53212600) (EudraCT2020-004701-31)